Erasca ( (ERAS) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Erasca’s stock is sinking as investors react to news that a patient died from treatment-related causes in a Phase 1 trial of its lead cancer drug, ERAS-0015. The safety scare has raised serious questions about the future of one of the company’s most important experimental therapies.
Adding to the pressure, rival Revolution Medicines has accused Erasca of patent infringement and trade-secret theft tied to the same program. The threat of costly intellectual-property litigation, on top of clinical risk, has badly shaken market confidence in Erasca’s RAS-focused pipeline.
More about Erasca
YTD Price Performance: 186.29%
Average Trading Volume: 6,579,705
Technical Sentiment Signal: Buy
Current Market Cap: $3.31B
For further insights into ERAS stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.